uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows mixed signals: strong cash position and potential for AMT-130, but increased expenses and uncertain regulatory outcomes. The Q&A reveals robust testing and a motivated community for Huntington's, but concerns about dose toxicity and unclear FDA interactions. The strategic plan indicates optimism for future approvals, but the lack of EMA/MHRA engagement and management's evasiveness on key questions temper expectations. Overall, the neutral sentiment reflects positive long-term prospects but short-term uncertainties.
Key Financial Performance
Revenue for Q3 2025 $3.7 million, an increase of $1.4 million (approximately 60.87%) year-over-year. The increase was driven by a $1.5 million rise in license revenues, partially offset by a $0.1 million decrease in collaboration revenues.
Cost of contract manufacturing revenues for Q3 2025 $0, compared to $0.8 million in Q3 2024. This change is due to the divestment of the Lexington facility in July 2024, which led to these costs being recorded net of revenue within other expenses.
Research and development expenses for Q3 2025 $34.4 million, an increase of $3.8 million (approximately 12.42%) year-over-year. The increase was driven by a $10.1 million rise in direct R&D expenses, including $6.6 million related to preparation for the BLA submission of AMT-130, offset by decreases of $3.4 million in severance costs and $3 million in costs related to disposables, facilities, and other expenses.
Selling, general and administrative expenses for Q3 2025 $19.4 million, an increase of $7.8 million (approximately 67.24%) year-over-year. This was primarily due to a $2.4 million rise in employee-related expenses and a $4.9 million increase in professional fees, including $3 million for potential commercialization of AMT-130 in the U.S.
Cash, cash equivalents, and investment securities as of September 30, 2025 $694.2 million, an increase of $326.7 million (approximately 88.88%) from $367.5 million as of December 31, 2024. The increase was primarily due to net proceeds of $404.2 million from public offerings in 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AMT-130 for Huntington's disease: Positive top-line data from Phase I/II study showed a 75% slowing of disease progression at 3 years (cUHDRS) and 60% slowing (total functional capacity). However, FDA feedback has introduced uncertainty regarding BLA submission.
AMT-260 for mesial temporal lobe epilepsy: Initial data showed promising reduction in seizure frequency over 5 months with no serious adverse events. Recruitment expanded to a second cohort at a higher dose.
AMT-191 for Fabry disease: Phase I/IIa trial showed supraphysiological alpha-Gal A enzyme activity, stable plasma lyso-Gb3 levels, and manageable safety profile. Patients successfully withdrawn from enzyme replacement therapy.
AMT-162 for SOD1 ALS: Enrollment paused due to dose-limiting toxicity observed in one patient. Data collection continues.
U.S. market preparation for AMT-130: Focus on stakeholder engagement, including treatment centers, payers, and patient advocacy groups. Planning for potential launch.
Expansion to EU and UK markets: Exploring additional potential markets for AMT-130 outside the U.S.
Financial performance: Revenue increased to $3.7 million in Q3 2025 from $2.3 million in Q3 2024. Cash reserves at $694.2 million, sufficient to fund operations into 2029.
R&D and administrative expenses: R&D expenses rose to $34.4 million, driven by BLA preparation for AMT-130. Administrative expenses increased to $19.4 million due to commercialization efforts.
Regulatory strategy for AMT-130: Engaging with FDA to clarify next steps after unexpected feedback. Planning to advance discussions with EU and UK regulatory agencies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
FDA Feedback on AMT-130: The FDA no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control may be adequate to support a BLA submission. This unexpected feedback introduces uncertainty into the regulatory approval timeline for AMT-130, potentially delaying its availability to patients.
AMT-162 for SOD1 ALS: Enrollment in the Phase I/II EPISOD1 trial of AMT-162 has been voluntarily paused due to a dose-limiting toxicity observed in one patient, resulting in a serious adverse event. This raises concerns about the safety profile of AMT-162 and its future development.
Increased R&D and SG&A Expenses: Research and development expenses increased by $3.8 million, and selling, general, and administrative expenses rose by $7.8 million compared to the same period in 2024. These rising costs, particularly related to the preparation for the BLA submission and potential commercialization of AMT-130, could strain financial resources if revenue growth does not keep pace.
Regulatory and Market Uncertainty for AMT-130: The uncertainty surrounding the FDA's approval process for AMT-130 and the need to engage with other regulatory agencies in the EU and UK could delay market entry and impact the company's strategic plans.
Paused Enrollment in AMT-162 Trial: The pause in enrollment for AMT-162 due to safety concerns may delay the program's progress and affect investor confidence in the company's pipeline.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
AMT-130 for Huntington's Disease: The company plans to urgently engage with the FDA to discuss next steps for the BLA submission for AMT-130. They expect to receive formal meeting minutes from the FDA within 30 days. The company remains committed to working collaboratively with the FDA to bring AMT-130 to patients in the U.S. as rapidly as possible. Additionally, they are planning to advance discussions with regulatory agencies in the EU and the U.K. for potential market launches outside the U.S.
AMT-260 for Mesial Temporal Lobe Epilepsy: The company has activated 17 recruiting sites in the U.S. and completed enrollment of the first 3 patients in the first cohort. Recruitment has expanded to include mesial temporal lobe epilepsy in the dominant hemisphere, and a second cohort at a higher dose has been initiated. Updated data from the study is expected in the first half of 2026.
AMT-191 for Fabry Disease: Enrollment in the second lower dose cohort has been completed, and a third cohort is currently enrolling. Updated data from the ongoing Phase I/IIa trial is expected in the first half of 2026.
AMT-162 for SOD1 ALS: Enrollment in the Phase I/II EPISOD1 trial has been voluntarily paused following a serious adverse event in one patient. The company will continue to collect and evaluate data from treated patients.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:To what extent have the treatment results been stress tested, and how was the external control arm constructed to avoid bias?
A:The results were rigorously tested using propensity score-matching with Enroll-HD, which provides robust data due to its size. Sensitivity testing was conducted with different matching and weighting methods, regional differences, comorbidities, and comparisons to TRACK and PREDICT studies. The findings were consistent, demonstrating robustness. Additionally, numerical changes from baseline in the patient population were compared to published data, showing a small magnitude of change compared to placebo or untreated subjects.
Q:What happened in AMT-162, and what were the dose differences between the first and second cohorts?
A:The company has not disclosed all dose data but noted dorsal root ganglion toxicity at the middle dose, which was about threefold higher than the low dose. This toxicity is a known adverse event for this route of administration. The company is monitoring the data and will discuss next steps with experts and the IDMC, aiming to provide answers in the first half of next year. The capsid and mode of administration are different from other programs.
Q:What details are expected from the final meeting minutes in the next 30 days?
A:The company hopes the minutes will reflect the conversation with the FDA, outline the FDA's concerns, and provide guidance on addressing these concerns in a subsequent meeting.
Q:Did prior meeting minutes confirm the ability to file for accelerated approval based on the cUHDRS?
A:Yes, in the November 2024 multidisciplinary meeting, the FDA confirmed that data from the Phase I/II study compared to an external control could serve as the primary basis for a BLA submission. The composite UHDRS was deemed an acceptable intermediate clinical endpoint for accelerated approval. Specifics on the statistical analysis plan were discussed in the April 2025 meeting.
Q:What needs to happen in the next few weeks to continue investing in Huntington's program?
A:The company is committed to collaborating with the FDA to expedite a BLA submission. They believe AMT-130 can benefit patients and have compelling data showing a meaningful slowing of disease progression. They aim to address FDA concerns and bring the therapy to patients as quickly as possible.
Q:Is the ALS program using intrathecal delivery, and is dorsal root ganglion toxicity known for this route? How motivated is the patient and doctor community for the Huntington's program?
A:Yes, the ALS program uses intrathecal delivery, and dorsal root ganglion toxicity is a known risk for this route. The patient and physician community for Huntington's is highly motivated, with a significant unmet medical need. They are collaboratively working to move the therapy forward despite recent disappointments.
Q:Has the company received any EMA or MHRA feedback on accepting the same data set and external control for AMT-130? Could ex-U.S. submissions proceed ahead of FDA approval?
A:The company has not yet engaged with the EMA or MHRA but plans to do so after prioritizing the FDA. They are committed to advancing regulatory discussions globally to bring the therapy to patients as quickly as possible.
Q:What was discussed in the recent FDA meeting, and has the FDA seen more data than what has been publicly shared?
A:The company cannot comment on specific meeting details but hopes for clarity from the meeting minutes. The data submitted to the FDA was consistent with publicly shared data, with some additional sensitivity analyses not yet presented publicly.
Q:Review of Unclear Management Responses
A:Management avoided directly answering questions about the specific details of the recent FDA meeting, including why the FDA no longer supported the BLA path and what had changed. They also did not disclose all dose data for AMT-162 or provide detailed insights into the sensitivity analyses shared with the FDA.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AMT comparison
AMT disease
AMT line
AMT potential
AMT slowing
FDA Phase
FDA step
HD patient
II study
Kapusta
Phase II
United States
advocacy
communication
community announcement
comparison control
control evidence
discipline
discussion meeting
dose AMT
enthusiasm
evidence support
feedback AMT
investigator patient
launch AMT
level
line Phase
milestone
monitoring committee
month follow
month period
partner
patient cohort
patient dose
patient family
period increase
potential AMT
study AMT
submission AMT
transparency
QURE Transcript
uniQure N.V. (QURE) Q1 2026 Earnings Call Transcript
Unknown5-5
Despite a 15% YoY revenue increase and reduced net loss, the earnings call highlighted significant risks, including regulatory challenges and economic uncertainties, which may offset the positive financial performance. No new partnerships or shareholder return plans were discussed, and the strategic initiatives were unclear. The Q&A provided no additional insights to alter this neutral outlook.
uniQure N.V. (QURE) Q4 2025 Earnings Call Transcript
Unknown3-2
The earnings call reveals a mixed outlook. Financial health shows increased cash reserves due to public offerings, but expenses have risen. Product updates include progress in trials but also a pause due to adverse events. The Q&A highlights regulatory challenges and uncertainties in trial designs. While there is potential for market expansion, lack of clear guidance and unresolved FDA concerns temper optimism. Overall, the sentiment remains neutral due to mixed signals from financial health and regulatory hurdles.
uniQure N.V. (QURE) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call shows mixed signals: strong cash position and potential for AMT-130, but increased expenses and uncertain regulatory outcomes. The Q&A reveals robust testing and a motivated community for Huntington's, but concerns about dose toxicity and unclear FDA interactions. The strategic plan indicates optimism for future approvals, but the lack of EMA/MHRA engagement and management's evasiveness on key questions temper expectations. Overall, the neutral sentiment reflects positive long-term prospects but short-term uncertainties.
uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript
Unknown7-29
The earnings call summary shows mixed signals. The basic financial performance is weak due to a significant revenue decline, but the company maintains a strong cash position. Product development is promising with advanced pipeline stages and FDA breakthrough designation. Market strategy and shareholder return plans are unclear or not emphasized. The Q&A reveals optimism in regulatory and commercial prospects but lacks clarity on key metrics like NfL. Given these mixed factors, the stock is likely to remain stable in the short term, leading to a neutral prediction.
QURE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
